



GE Healthcare

**Clinical Study Protocol:**

**Clinical Evaluation Of The OEC Elite Vascular Mobile Fluoroscopy System**

**(Study # 104-2016-PTHS-0005)**

**Version: 2.0; 13/Feb/2017**

**Sponsor:** General Electric Company, acting through its GE Healthcare Business  
3000 N. Grandview Blvd  
Waukesha, WI 53188

**Sponsor Contact:** Beth Heckel, Clinical Affairs Project Manager  
*Tel:* 1-262-312-7269  
*E-mail:* Beth.Heckel@med.ge.com

**Medical Monitor:** Ron von Jako, MD, PhD, Medical Director  
*Tel:* 1-617-669-3200  
*E-mail:* Ron.VonJako@med.ge.com

**Investigational Device/Product:** OEC Elite™ Mobile Fluoroscopy System

**Modality:** Surgery

**FOR QUALIFIED INVESTIGATORS, STUDY STAFF, AND THEIR  
ETHICS COMMITTEE(S) ONLY**

**CONFIDENTIALITY STATEMENT**

Information in this RESEARCH STUDY PROTOCOL is for investigators, site personnel involved with the study, ethics committee(s), and/or their authorized representative(s) except as required to obtain consent from study participants or as otherwise required by law. Once signed, the terms of the protocol are binding for all parties.

**Study Title:** Clinical Evaluation Of The OEC Elite Vascular Mobile Fluoroscopy System  
**Study No:** 104-2016-PTHS-0005



The Sponsor and Investigator have approved this protocol version, and I confirm hereby to conduct the study according to the protocol and in accordance with applicable principles of the World Medical Association Declaration of Helsinki and Good Clinical Practice (GCP) guidelines as per ISO 14155:2011, any conditions of approval imposed by the reviewing EC or governing regulatory body, and applicable laws and regulations. The investigator should not deviate from this protocol except for emergency use. I have read and understood and agree to abide by all the conditions and instructions contained in this protocol.

**Local Principal Investigator at study site:**

Investigator Signature

Date

Print Name

Site Name, Department, Address



## Table of Contents

<b>Document and Version Control .....</b>	<b>5</b>
<b>List of Abbreviations and Terms.....</b>	<b>6</b>
<b>Study Synopsis .....</b>	<b>7</b>
<b>Administrative Structure of Investigation.....</b>	<b>9</b>
<b>1. Background and Justification.....</b>	<b>10</b>
1.1 Mobile Fluoroscopy and Vascular Procedures .....	10
1.2 Pre-Clinical Trials and Previous Clinical (human) Experience .....	10
1.3 Controls and Minimization of Bias.....	11
<b>2. Device/Product Description .....</b>	<b>12</b>
2.1 Identity, Mechanism, and Function .....	12
2.2 Intended Use.....	13
2.3 Concomitant/Ancillary Administrations .....	13
2.4 Accountability .....	13
2.5 Anticipated Risks and Benefits.....	13
2.6 Purpose of the Study .....	14
2.7 Study Endpoints .....	14
2.8 Summary of Study Design.....	14
<b>3. Study Design.....</b>	<b>15</b>
3.1 Study Population .....	15
3.2 Number Subjects/Cases .....	15
3.3 Protection of Vulnerable Subjects .....	15
3.4 Eligibility Criteria .....	15
3.5 Recruiting and Screening.....	16
3.6 Criteria for Withdrawal/Discontinuation .....	16
<b>4. Study Procedures .....</b>	<b>16</b>
4.1 Subject Preparation .....	16
4.3 Follow-up.....	17
4.4 Malfunction/Error Handling.....	17
<b>5. Study Data Collection and Assessments .....</b>	<b>18</b>
5.1 Operating Physicians .....	18
<b>6. Qualification and Training Plan.....</b>	<b>18</b>
6.1 Staff Qualifications .....	18
6.2 Training Plan for the Protocol and Research Device/Product.....	18
6.3 Case Report Form .....	18
<b>7. Safety.....</b>	<b>19</b>
<b>8. Ethical Conduct of the Study.....</b>	<b>21</b>
8.1 Ethics Committee .....	21
8.2 Regulatory Agencies and Competent Authority .....	21
8.3 Management of Protocol Modifications and Amendments .....	22
8.4 Participant Information and Informed Consent .....	22
8.5 Early Termination of the Study.....	22
<b>9. Statistical Methods .....</b>	<b>23</b>
9.1 Statistical Hypothesis.....	23
9.2 Sample Size Determination.....	23
9.3 Statistical Analysis .....	23
9.4 Handling of Missing Data .....	23
9.5 Deviation(s) from the Original Statistical Plan.....	23
<b>10. Quality Assurance and Control.....</b>	<b>23</b>
10.1 Data Management .....	23



---

<b>11. Monitoring Plan .....</b>	<b>24</b>
11.1 Confidentiality and Data Protection.....	24
11.2 Publication Policy .....	25
<b>References .....</b>	<b>26</b>
<b>Appendix A – Study Site and Investigator List .....</b>	<b>27</b>



## DOCUMENT AND VERSION CONTROL

This section records all changes made to the protocol for a specific study. In the table below, record every relevant change by indicating what changes were made.

Revision	Date	Revision Author	Comments/Changes
1.0	13/Feb/2017	Chris Rogness	Research Engineer – This is the initial version.
2.0	13/Feb/2017	Chris Rogness	Update objectives and endpoints in Study Synopsis and Section 2.6, and procedures in Sections 1.1 and 4.2.



---

## LIST OF ABBREVIATIONS AND TERMS

AE	Adverse Event
ADE	Adverse Device Effect
ALARP	As Low as Reasonably Practicable
AMA	American Medical Association
CA	Competent Authority
CAPM	GE Clinical Affairs Project Manager
CCG	Case Report Form Completion Guidelines
CFR	Code of Federal Regulations
CHF	Clinical History File (synonymous with e-Trial Master File)
CRF	Case Report Form
DCF	Data Clarification Form
DICOM	Digital Imaging and Communications in Medicine
DMP	Data Management Plan
EC	Ethics Committee
EU	European Union
FDA	United States Food and Drug Administration
GCP	Good Clinical Practice (see ISO 14155:2011)
GE	General Electric
GEHC	General Electric Healthcare
ICF	Informed Consent Form
ISO	International Standards Organization
MWS	GE MyWorkshop Internal Documentation System
PI	Principal Investigator
SADE	Serious Adverse Device Effect
SAE	Serious Adverse Event
SRG	Surgery
US	United States
USADE	Unexpected Serious Adverse Device Effect



STUDY SYNOPSIS	
<b>Sponsor:</b>	General Electric Company, acting through its GE Healthcare Business
<b>Research Type:</b>	This is a Clinical, open label, non-randomized, prospective research study.
<b>Regulatory Status:</b>	<p>This is a pre-market research study of the following devices/products:</p> <p><i>Pre-market:</i> OEC Elite™ CFD Mobile Fluoroscopy System – Vascular Configuration</p> <p><i>Post-market:</i> Not applicable</p>
<b>Background and Rationale:</b>	The purpose of this study is to collect feedback on imaging guidance adequacy from physicians who use the OEC™ CFD Mobile Fluoroscopy System in the Vascular Configuration to perform surgical procedures for which the use of mobile fluoroscopy is prescribed per standard of care.
<b>Procedures/ Methods:</b>	<p>Up to 170 eligible subjects will be enrolled and have their clinically indicated procedure completed using the investigational device.</p> <p>Following completion of each subject's procedure, the investigators will complete a survey specific to the workflow and guidance adequacy of the OEC Elite device. The survey will consist of a series of questions on the use of the system as well as anonymized image data.</p> <p>After all subjects' procedures are completed at a given site, the site investigator will review survey data from the study subjects enrolled at the site and document his/her assessment of the overall acceptability of the system for use in a clinical environment.</p> <p>There is no statistical hypothesis being tested in this study. Results will be summarized using descriptive statistics.</p>
<b>Objectives:</b>	<p><i>Primary:</i> To collect investigator feedback on imaging guidance adequacy of the OEC Elite during clinical procedures.</p> <p><i>Secondary:</i> To collect image data acquired during clinical procedures.</p> <p>To collect investigator feedback via surveys on the use of the system during clinical procedures.</p>
<b>Endpoints:</b>	<p><i>Primary:</i> The primary endpoint is the per-subject investigator report of imaging guidance adequacy to complete the procedure (Y/N).</p> <p><i>Secondary:</i> Total number of evaluable surveys. Total number of images collected.</p> <p><i>Safety:</i> Safety will be assessed by AE and SAE occurrence</p>



<b>Eligibility criteria:</b>	<b>Inclusion criteria:</b> <ol style="list-style-type: none"> <li>1. Male or female between the ages of 18 and 75 years (<math>\geq 18</math> and <math>\leq 75</math> years old);</li> <li>2. Clinical indication for a vascular, gastrointestinal (GI), urology or pain management procedure for which mobile fluoroscopy has been prescribed;</li> <li>3. Able and willing to comply with study procedures; and</li> <li>4. Able and willing to provide written informed consent to participate.</li> </ol>	<b>Exclusion criteria:</b> <ol style="list-style-type: none"> <li>1. Pregnant or suspected to be pregnant based on the opinion of and as documented by a medically qualified physician investigator;</li> <li>2. Expected to be at increased risk due to study participation (e.g. due to allergies, sensitivities), in the medical opinion of the investigator; or</li> <li>3. Previously participated in this study, or enrolled in another active GEHC study or other research study that could be expected to interfere with participation in study procedures, in the opinion of the investigator.</li> </ol>
<b>Sample size and Sites:</b>	<p>Up to 170 subjects from two (2) sites will be included in this study.</p> <p>The sample size is based on the Sponsor's previous clinical experience and the expectation that a sufficient number of surveys from representative procedures will be acquired for the purposes of clinical evaluation.</p>	
<b>Study duration:</b>	<p>The study is expected to last approximately two (2) months.</p>	





ADMINISTRATIVE STRUCTURE OF INVESTIGATION		
Clinical Affairs Project Manager <b>(Sponsor Contact):</b>	<b>Beth Heckel</b> <i>Tel:</i> 1-262-312-7269 <i>e-mail:</i> Beth.Heckel@med.ge.com	<b>GE Healthcare (GEHC)</b> <i>Address:</i> 3000 N Grandview Blvd Waukesha, WI 53188, US
Research Manager:	<b>Jon Lea, PhD</b> <i>Tel:</i> 1-801-536-4791 <i>e-mail:</i> jon.lea@med.ge.com	<b>GEHC</b> <i>Address:</i> 384 Wright Brothers Drive Salt Lake City, UT 84116, US
Medical Monitor:	<b>Ron von Jako, MD, PhD</b> <i>Tel:</i> 1-617-669-3200 <i>e-mail:</i> Ron.VonJako@med.ge.com	<b>GEHC</b> <i>Address:</i> 1100 Technology Park Drive Billerica, MA 01821, US



## 1. BACKGROUND AND JUSTIFICATION

### 1.1 Mobile Fluoroscopy and Vascular Procedures

Over the past 25 years, fluoroscopically guided interventional procedures have rapidly increased worldwide.<sup>2, 3</sup> Fluoroscopy guidance provides surgeons and interventional specialists with the improved ability to assess anatomy and implant materials,<sup>4</sup> as well as guide catheters, guidewires, and stents through small vessels and pathways throughout the human body.<sup>2</sup>

In modern angiography, fluoroscopy provides necessary imaging guidance during dynamic vascular procedures, such as aortic aneurysm repairs, percutaneous artery angioplasty, and angiographic examinations.<sup>5</sup> Preoperative fluoroscopy may also be necessary for arteriography of the aorta and other vessels to determine precise anatomical relations when the proximal landing zone of a stent graft cannot be determined by non-invasive imaging.<sup>6</sup> Furthermore, peripheral angiography is regarded as the most accurate imaging tool for definitive diagnostics and preoperative planning of surgical and endovascular interventions in patients with advanced arterial disease.<sup>7</sup>

Gastrointestinal imaging has significantly evolved since the 1950s and fluoroscopy maintains a critical role in GI radiology. Mobile fluoroscopy is accepted as safe and effective for use during intraoperative cholangiography and external percutaneous biliary drainage procedures, and fluoroscopic imaging of upper gastrointestinal series has demonstrated better tumor localization when compared to endoscopic examination.

In contemporary clinical practice, complicated urologic procedures, including endourologic procedures such as retrograde cholangiopancreatography and upper urinary tract procedures are increasingly being performed using mobile C-arm fluoroscopy. With the advent of more complex fluoroscopically guided procedures, new interventional techniques and devices, such as the device under investigation in this study, are being developed and introduced to the market.

This prospective clinical study is being conducted to acquire image guidance adequacy data from physicians conducting clinically-indicated vascular, gastrointestinal (GI), urology and pain management procedures for engineering use, as deemed appropriate by the Sponsor, for the investigational OEC Elite Mobile Fluoroscopy System (OEC Elite) in the vascular configuration. Clinical procedures included in this study will involve three (3) anatomical regions of interest – extremities and neck, thorax, and abdomen and pelvis. These regions are being targeted because they represent the range of clinical applications and anatomical regions intended for OEC Elite in the vascular configuration.

### 1.2 Pre-Clinical Trials and Previous Clinical (human) Experience

GE Healthcare (GEHC), the study Sponsor, is a manufacturer of mobile fluoroscopy equipment and has extensive experience in conducting clinical trials.

A GEHC-sponsored study of human cadaveric tissue was conducted as part of feasibility and optimization of the investigational device's predicate, the OEC 9900 Elite (Study Title: A Diagnostic Capability Bench Study Of An SSXI Mobile Fluoroscopy System And The OEC® 9900 Elite Mobile Fluoroscopy System; GEHC Study Number: 104-2014-GES-0003). A preclinical study using the swine animal model was recently conducted by the Sponsor for software optimization of the vascular configuration prior to implementing investigational OEC Elite in the vascular configuration in the clinical setting (Study Title: A Preclinical Imaging Study of the OEC Elite Vascular System; GEHC Study Number 104-GES-2016-0001).



---

## 1.3 Controls and Minimization of Bias

All reasonable attempts will be made to control and minimize bias during this study, including the following:

- Subjects will be consecutively enrolled from the patients screened until the accrual quota is filled, with the intent of limiting selection bias;
- Spectrum bias will be limited by using a population expected to be representative of the general population at the investigational site, without regard to race or ethnicity.



## 2. DEVICE/PRODUCT DESCRIPTION


### 2.1 Identity, Mechanism, and Function

**Name:** OEC Elite™ Mobile Fluoroscopy System  
**Modality/Type:** Surgery  
**Manufacturer:** GE OEC Medical Systems, Salt Lake City, UT, USA  
**Software version:** The most current version available will be used.  
**Regulatory Status:** Pre-market

**Note:** A record of number of devices issued, along with applicable identification numbers (e.g. serial/lot/batch) and components/accessories used in this study will be retained by the Sponsor as part of the clinical history file (CHF), as required by applicable laws and regulations.

The OEC Elite™ Mobile Fluoroscopy System (OEC Elite) is a medical device centrally comprised of a mobile C-arm with flat-panel detector and a mobile workstation that displays resultant images. The device includes hardware and software capable of generating and receiving x-ray signals to produce images of bone and living tissues, and a mobile workstation that includes image display and user interface. The central difference between the predicate OEC 9900 Elite device and the investigational system is the replacement of an image intensifier detector with a flat-panel detector.

For this study, the OEC Elite (Figure 1) will be provided to the investigational sites in the vascular configuration in either the 21-cm and 31-cm flat panel detectors.



**Figure 1** – Investigational OEC Elite Mobile Fluoroscopy System

The research device, instructions for use, or packaging shall indicate that the research device is for use in a research investigation, in accordance with applicable regulations in Canada per Medical Device Regulations (SOR/98-282), Part 3, Sections 79-88 and other applicable laws and regulations.

The investigational device will be exclusively used for research procedures and only as set forth in an Ethics Committee (EC) approved study protocol, in accordance with applicable laws and regulations.



## **2.2 Intended Use**

The OEC Elite Mobile Fluoroscopy System is designed to provide fluoroscopic and digital spot images of adult and pediatric populations during diagnostic, interventional, and surgical procedures. Examples of a clinical application may include: orthopedic, gastrointestinal, endoscopic, urologic, neurologic, vascular, critical care, and emergency procedures.

This study will include vascular, gastrointestinal (GI), urology and pain management procedures in an adult population. Study procedures will be conducted in accordance with the site's standard of care.

## **2.3 Concomitant/Ancillary Administrations**

### **2.3.1 Medications and Biologic Products**

No medications or biologic products will be administered as part of study procedures.

### **2.3.2 Laboratory Tests and Sample Processing**

No laboratory tests or sample processing is planned as part of the study procedures.

## **2.4 Accountability**

Accurate and adequate records will be maintained for all devices, from time of shipment to the sites until return or disposal of all devices issued by the Sponsor as part of this study, as required by applicable laws and regulations. The Principal Investigator will be ultimately responsible for the security and integrity of research devices at the investigational site during the study.

### **2.4.1 Issuance**

The Sponsor will provide the site with devices, including necessary hardware and software components of the device. The Sponsor will provide necessary maintenance for the investigational device(s) installed at the sites. GE technical support will be available, as needed, to maintain integrity of study data.

### **2.4.2 Disposition**

Upon completion of the study, Sponsor-provided devices at the investigational sites will be de-installed by Sponsor-authorized engineers and returned to the Sponsor, or otherwise dispositioned, in accordance with applicable laws and regulations. Identifiable subject information will be removed from the device(s) prior to dispositioning devices.

## **2.5 Anticipated Risks and Benefits**

The device under study has undergone risk assessment, in accordance with International Standards Organization (ISO) 14971:2012, and risks have been mitigated to levels as low as reasonably practicable (ALARP).

The investigational OEC Elite is expected to present similar potential risks to patients, operators, or others in this study as the predicate commercial device, OEC 9900 Elite, when used under similar clinical indications for use. The risks of study participation are not expected to be different than those of non-study procedures. Because basic image guided fluoroscopy will be used for conventional procedure applications, there will be no post-trial care or follow-up required by this study.

As with all x-ray devices, OEC Elite uses the minimum possible ionizing x-ray radiation dose, which is within acceptable limits set forth by applicable local laws and regulations necessary to complete a procedure. Because the radiation dose and procedural duration widely vary for the procedures included in this study, there is no prospective per-procedure maximum radiation dose or duration prescribed by this protocol. All



procedures will be conducted per the clinical standards of the site and the medical discretion of physicians performing the clinically indicated study procedures.

In the unlikely event that a device error prevents or impairs image acquisition, it is possible that a subject may require alternative or additional imaging to complete an intervention or exam. If imaging is not adequate or diagnostic-quality images cannot be obtained using the investigational device, the subject will not undergo additional investigational imaging. Necessary medical care will be provided by the sites, and equivalent, site-provided commercial fluoroscopy systems (e.g. the predicate device or equivalent) will be readily available throughout the study.

Subjects who undergo additional or elongated imaging procedures may be at a small increased risk because of additional x-ray exposure and possible additional procedure time, which may also impact the duration and/or dosages of anesthesia and contrast administration.

Subjects are not expected to benefit directly from study participation; however, the results may benefit future patients by helping to better understand the device under study.

### **2.5.1 Risk Category and Rationale**

In Canada, the OEC Elite Mobile Fluoroscopy System is a Class III medical device, as defined by Schedule 1, Part 1, Rule 8 of the Medical Devices Regulations (SOR/98-282). Use of OEC Elite is not expected to pose significant risk to human subjects in accordance with the standards of Health Canada's Medical Device Regulations, Part 3 – Medical Devices for Investigational Testing Involving Human Subjects (SOR/98-282, §79-88).

## **2.6 Purpose of the Study**

The purpose of the study is to collect survey data on the use of the OEC Elite based on the routine clinical use of the device.

### **2.6.1 Primary Objective:**

- To collect investigator feedback on imaging guidance adequacy of the OEC Elite during clinical procedures.

### **2.6.2 Secondary Objective(s):**

- To collect image data acquired during clinical procedures.
- To collect investigator feedback via surveys on the use of the system during clinical procedures.

## **2.7 Study Endpoints**

### **2.7.1 Primary Endpoints:**

The primary endpoint is the per-subject investigator report of imaging guidance adequacy to complete the procedure (Y/N).

### **2.7.2 Secondary Endpoints:**

The secondary endpoints are the total number of surveys reflecting the investigator opinion of procedures performed and the image data collected.

## **2.8 Summary of Study Design**

This is a pre-market, Clinical, open label, prospective, non-randomized research study conducted at two (2) sites in Canada.



## 3. STUDY DESIGN

### 3.1 Study Population

The study population will be adults undergoing vascular, gastrointestinal (GI), urology or pain management procedures for which use of the OEC Elite system in the vascular configuration would be prescribed. This population is expected to be representative of the general population that would require mobile fluoroscopic imaging with C-arm devices, such as OEC Elite. Pediatric patients (i.e. patients younger than 18 years old) will not be enrolled in this study.

### 3.2 Number Subjects/Cases

Up to 170 subjects may be enrolled at all sites. Enrollment may be discontinued at any time prior to reaching 170 subjects at the discretion of the sponsor.

### 3.3 Protection of Vulnerable Subjects

Vulnerable subjects are individuals whose willingness to volunteer in a clinical investigation could be unduly influenced by the expectation, whether justified or not, of benefits associated with participation or of retaliatory response from senior members of a hierarchy in case of refusal to participate.

The Sponsor shall avoid improper influence on, or inducement of, the subject, monitor, any investigator(s), or other parties participating in, or contributing to, the clinical investigation.

All investigators shall avoid improper influence on, or inducement of, the subject, Sponsor, monitor, other investigator(s), or other parties participating in, or contributing to, the clinical investigation.

This study does not examine any groups of subjects who are vulnerable subjects in the country in which the study is being conducted.

### 3.4 Eligibility Criteria

#### 3.4.1 Inclusion Criteria

Subjects who meet all the following inclusion criteria may be included:

- 1) Male or female between the ages of 18 and 75 years ( $\geq 18$  and  $\leq 75$  years old);
- 2) Clinical indication for a vascular, gastrointestinal (GI), urology or pain management procedure for which mobile fluoroscopy has been prescribed;
- 3) Able and willing to comply with study procedures; and
- 4) Able and willing to provide written informed consent to participate.

#### 3.4.2 Exclusion Criteria

Subjects who meet any of the following exclusion criteria will be excluded:

- 1) Pregnant or suspected to be pregnant based on the opinion of and as documented by a medically qualified physician investigator;
- 2) Expected to be at increased risk due to study participation (e.g. due to allergies, sensitivities), in the medical opinion of an investigator; or





- 3) Previously participated in this study, or enrolled in another active GEHC study or other research study that could be expected to interfere with participation in study procedures, in the opinion of the investigator.

### 3.5 Recruiting and Screening

Subjects will be recruited for potential enrollment at the site from an adult population scheduled for a clinical procedure with mobile fluoroscopy. Subjects will be screened for enrollment against the inclusion and exclusion criteria, and enrollment determinations will be made by the site investigator. Recruitment, screening, and enrollment will be conducted per the standard procedures of the investigational site. All participation will be voluntary.

Following recruitment, a subject will be considered enrolled (the point of enrollment) once he/she signs and dates the informed consent form (ICF). Once enrolled, the subject will be assigned a unique subject number, which will not contain information that could identify him/her (e.g. subject name or date of birth). The unique subject number will be used to label case report form (CRF) data for the subject throughout his/her participation in the study.

### 3.6 Criteria for Withdrawal/Discontinuation

A subject may withdraw from study participation at any time, for any reason. The investigator may withdraw a subject at any time, for any reason. The reasons for withdrawal and discontinuation for any subject shall be recorded and reported to the Sponsor. The EC should be notified per their notification of subject withdrawal policy.

If a subject withdraws or is withdrawn, all efforts will be made to complete and report study data up to the time of withdrawal. A complete final evaluation at the time of the subject's withdrawal shall be made and recorded on a CRF. If the reason for withdrawal is related to an adverse event (AE) or serious adverse event (SAE), monitoring of the subject will continue until the outcome is evident.

Any data collected for the subject, up until the time of withdrawal or discontinuation, may still be included in the study results and provided to the Sponsor, unless the subject requests that their data not be used. The site shall document all requests by subjects regarding their data use.

## 4. STUDY PROCEDURES

### 4.1 Subject Preparation

Study staff will confirm that each subject is eligible and willing to comply with applicable site requirements prior to starting study procedures. No preparation beyond that required by the investigational site is required before procedures.

### 4.2 Description of Study Procedures

Each subject will undergo his/her clinically indicated vascular, gastrointestinal (GI), urology and pain management procedure with fluoroscopic imaging conducted using the investigational OEC Elite device. Prescribed treatments (e.g. contrasts, anesthesia) will be administered according to the standard of care.

#### 4.2.1 Anatomical Regions of Interest and Representative Procedures

For the purposes of this study, representative procedures will involve three grouped anatomical regions – extremities and neck, thorax, and abdomen and pelvis. Procedures are expected to be distributed across all anatomy but this is not required.





#### 4.2.1.1 Extremities and Neck

The purposes of this study, **extremities and neck will be defined as:** anatomy of the arm, from shoulder to fingers; the leg, from below the hip to the toes; and the head, from the neck up.

**Procedures of the extremities and neck** may include, but are not limited to:

- Dialysis access
- Fistulagram (e.g., lower arm)
- Carotid endarterectomy

#### 4.2.1.2 Thorax

For this study, **thorax will be defined as** anatomy from the diaphragm to the bottom of the neck.

**Procedures of the thorax** may include, but are not limited to:

- Central line placement (e.g., peripherally inserted central catheter insertion)
- Pacemaker placement
- Pain management

#### 4.2.1.3 Abdomen and Pelvis

In this study, **abdomen and pelvis will be defined as** anatomy from, and including, the hip, abdomen, and up to the diaphragm.

**Procedures of the abdomen and pelvis** may include, but are not limited to:

- Endovascular aortic aneurysm repair (e.g., abdominal)
- Endovascular repair of aortic dissection (e.g., abdominal, thoracic)
- Bypass of aortoiliac occlusive disease
- Inferior vena cava filter
- Embolization (e.g., sub renal, uterine fibroid)
- Urologic procedures (e.g. cystectomy, urethrography)

### 4.3 Follow-up

No follow-up will be conducted as part of this study. Subjects will be followed for AEs from the time they enter the procedural room containing the investigational device until the study procedure ends and they exit the procedural room.

### 4.4 Malfunction/Error Handling

The sites should report the occurrence and resolution of any procedures terminated due to non-recoverable malfunctions (i.e. malfunctions or errors with OEC Elite II that prevent image collection and are not able to be immediately resolved by the device operator). The sites should also report recoverable errors (i.e. issues with the device that do not prevent image collection and are able to be resolved immediately by the device operator) and operator errors. The occurrence of any recoverable error, operator error, or non-recoverable malfunction will be reported on the subject's CRF.

In uncommon cases, the research procedures using the investigational device may need to be terminated unexpectedly. If the investigator suspects that a subject would be at increased risk, or that the subject's clinical procedure will not be able to be completed using the investigational device in this study, the investigator may terminate the procedure at any time and for any reason. In some cases, it may not be feasible to end a procedure; in which case, equivalent, site-provided commercial fluoroscopy equipment (such as the predicate device or equivalent) may be used. The sites will ensure that access to alternative commercial fluoroscopy equipment is maintained during all procedures. All patient care and management decisions for terminated



procedures will be made outside of this study according to the sites' standard clinical practices and the subject's regular physician's or investigator's medical judgment.

## **5. STUDY DATA COLLECTION AND ASSESSMENTS**

### **5.1 Operating Physicians**

At the completion of a procedure, the physician (e.g. interventional specialist or surgeon) conducting the procedure will provide feedback on the capability of the system by completing a survey. Survey data will be recorded on case report forms (CRFs).

## **6. QUALIFICATION AND TRAINING PLAN**

### **6.1 Staff Qualifications**

All members of the study staff participating in the conduct of the Clinical investigation shall be qualified by education, training, and/or experience to perform their tasks. Qualifications shall be documented appropriately, as per ISO 14155:2011.

### **6.2 Training Plan for the Protocol and Research Device/Product**

Before starting the study, the study staff will be trained on the clinical investigation requirements set forth in this study protocol, including completion of Informed Consent Forms (ICFs), CRFs, and other study documentation. Training will also be provided to ensure appropriate storage and handling of data, and all study staff will be required to be trained on Good Clinical Practice (GCP) guidelines per ISO 14155: 2011.

A record of all formal training will be stored in the Site Regulatory Binder and provided to the Sponsor for inclusion in the Sponsor's CHF. Documentation of training will include:

- Title of Training
- Training objectives
- Training logistics (trainer and training methods)
- Documentation of trainees
- Training content (e.g. device operation, protocol review and CRF completion)

Study staff directly operating or maintaining the research device will be trained based on device operation and safety. A copy of the device operator manual will be provided to the site along with Sponsor-provided training.

The PI will be ultimately responsible for execution of this study, in accordance with the protocol, and for device use in this study by members of the study staff.

### **6.3 Case Report Form**

The study procedure CRF will report the following:

- Basic demographic
- Type of procedure or technique being performed
- Anatomical region being imaged
- Contrast information
- User Evaluation Survey
- Guidance Adequacy



## 7. SAFETY

### 7.1 Anticipated Adverse Events

The study design is not expected to pose additional risk to patients above that required by routine diagnostic, surgical, or interventional procedures that are clinically indicated for the patient and related to use of the OEC Elite.

All subjects included in this study will require imaging during a diagnostic exam or surgery per their clinically indicated procedure. Intraoperative imaging with OEC Elite and similar commercial mobile C-arm devices produce ionizing radiation at levels generally considered safe, but in extremely rare cases, may pose risks of deterministic tissue effects (e.g. skin reddening, cataracts, and hair loss) and very small increases in lifetime cancer risk. These side effects would be risks whether or not patients participate in this study, and they are extremely rare when a mobile C-arm is used for procedures similar to the proposed study procedures. These risks generally occur only in patients exposed to excessive amounts of x-ray radiation in a short time or excessive amounts over a long period of time concentrated to a single region. These events are unusual for mobile C-arms.

Subjects may also require prescribed medications, such as contrast ("dye"), anesthesia, and other medicines that are not expected to change as a result from participation in this study. These medications have widely recognized side effects that include allergic reactions, itching, swelling, burning, bleeding, mental confusion, lung infection, stroke, heart attack, and other potentially serious metabolic complications. Patients would be at risk for these side effects whether or not they participate in this study. Patients will receive consultation on possible benefits and risks specific to their recommended procedures according to the standard of care outside of this study, and the procedures for this study will not influence these discussions.

Patient participation in this study is not expected to increase risks for side effects from imaging, contrast, anesthesia, or other medication administration or to negatively impact the results of the procedure compared to equivalent procedures performed outside of this study, using commercially available devices.

There are potential risks to subjects participating in this study that are associated with unexpected device issues or procedural complications. These risks include:

- Longer duration of patient procedures, which are expected to be minimal (accounting for time to transfer patient to alternative, commercial device and/or mitigate any other procedural or device issues) and are not expected to significantly increase the total duration of the procedure.
- Additional imaging, which could involve using an alternative, commercial system available at the site.
- Extension or interruption of regular medical care or medication administration, including prolongation; re-administration of medicines, including contrast, anesthesia, and other medicinal agents; or delay of ending anesthesia or other medications.

These events are expected to be rare, but the risks for side effects normally related to surgery, imaging, contrast, anesthesia, or other medication administration may be increased for affected patients. To minimize the impact of these risks, alternative, commercially available mobile fluoroscopy systems available at the sites will be placed in an accessible location during all procedures that use investigational devices.

There is always a chance of unexpected risks. Throughout the study, the Sponsor will evaluate and update safety information in study documents.

### 7.2 Adverse Event Definitions

**Adverse Event (AE):** any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory findings) in subjects, users or other persons, whether or not related to the investigational medical device [ISO 14155:2011 3.2]. This includes events related to the investigational device or



the comparator and to the procedures involved. For users or other persons, this is restricted to events related to the investigational medical device.

**Serious Adverse Event (SAE):** an adverse event that led to death; led to a serious deterioration in the health of the subject, that either resulted in a life-threatening illness or injury, a permanent impairment of a body structure or a body function, or in-patient or prolonged hospitalization, or medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to body structure or a body function; or led to fetal distress, fetal death or a congenital abnormality or birth defect. Planned hospitalization for a pre-existing condition, or a procedure required by the protocol without serious deterioration in health, is not considered a SAE [ISO 14155:2011 3.37].

**Adverse Device Effect (ADE):** an adverse event related to the use of an investigational medical device [ISO 14155:2011 3.1]. This includes any adverse events resulting from insufficient or inadequate instructions for use, deployment, implantation, installation, or operation, or any malfunction of the investigational medical device. This includes any event that is a result of a user error or intentional misuse of the investigational device [ISO 14155:2011 3.43].

**Serious Adverse Device Effect (SADE):** an adverse device effect that has resulted in any of the consequences characteristic of a serious adverse event [ISO 14155:2011 3.36].

**Device deficiency:** an inadequacy of a medical device with respect to its identity, quality, durability, reliability, safety, or performance, such as malfunctions, use errors, and inadequate labelling [ISO 14155:2011 3.15].

**Unanticipated serious adverse device effect (USADE):** a serious adverse device effect, which by its nature, incidence, severity, or outcome has not been identified in the current version of the risk analysis report [ISO 14155:2011 3.42]. In the United States, any serious adverse effect on health or safety or any life-threatening problem or death caused by, or associated with, a device, if that effect, problem, or death was not previously identified in nature, severity, or degree of incidence in the study documents, will be reported in accordance with 21 CFR §812.3 and applicable laws and regulations.

## 7.3 Documentation of Safety Events

All adverse events (AE), including all serious adverse events (SAE), are required to be collected, investigated, and documented during the study reporting period, as defined in the study procedure set forth in this protocol. Documentation will include:

- Description of Event
- Date of onset and resolution
- Severity (mild, moderate, or severe)
  - *Mild:* Symptom(s) barely noticeable to the subject or does not make the subject uncomfortable. The AE does not influence performance or functioning. Prescription drugs are not ordinarily needed for relief of symptom(s).
  - *Moderate:* Symptom(s) of a sufficient severity to make the subject uncomfortable. Performance of daily activities is influenced. Treatment of symptom(s) may be needed.
  - *Severe:* Symptom(s) of a sufficient severity to cause the subject severe discomfort. Treatment for symptom(s) may be given.
- Serious (yes/no)
- Causal relationship to investigational medical device? (not related, possibly related, or related)
  - *Not related:* The adverse event is reasonably expected to be related to (or caused by) a concurrent illness, effect of another device/drug or other cause, and is unlikely related to the investigational product.
  - *Possibly related:* The adverse event is reasonably expected to be related to the investigational product, and an alternative etiology is equally or less likely compared to the potential relationship to investigational product.



- *Related:* There is a strong relationship to investigational product or recurs on re-challenge, and another etiology is unlikely or there is no other reasonable medical explanation for the event.
- Treatment given and/or action taken (procedure stopped, withdrawn from study, or no action)
- Anticipated (yes/no)

## 7.4 Reporting of Safety Events and Device Deficiencies/Complaints

The following events are to be reported to the Sponsor within 72 hours of the event occurrence and to the EC per their policy:

- All SAEs and USADEs
- All device issues that could possible lead to an SAE

Additional follow-up information may be requested by the Sponsor. In addition, safety information may be shared with regulatory agencies and other participating sites, as required by applicable law and regulation.

## 7.5 Device Deficiencies

Device deficiencies should be reported to the study Sponsor contact identified on the cover page of this protocol. All device deficiencies will to be collected, fully investigated, and documented in the source document and appropriate Sponsor document during the study reporting period. The PI is responsible for notifying the Sponsor in the event that there is any device issue that could potentially lead to a SAE.

## 8. ETHICAL CONDUCT OF THE STUDY

The study will be carried out in accordance with the protocol and with principles enunciated in the current version of the Declaration of Helsinki; the guidelines of Good Clinical Practice (GCP) for medical devices, as set forth by ISO 14155:2011 and ISO 14971:2012; applicable requirements of Health Canada's Medical Device Regulations (SOR/98-282); and other applicable regulatory authority requirements of Canada, as necessary.

The study will be conducted and reported in accordance with applicable policies of the local Ethics Committee (EC) and governing regulatory authorities.

If national or regional EC requirements are less strict than the requirements of GCP, such as ISO 14155:2011 for medical devices, the Sponsor shall apply the requirements of this International Standard to the greatest extent possible, irrespective of any lesser requirements, and shall record such efforts.

### 8.1 Ethics Committee

The responsible site PI will ensure that approval from an appropriately constituted EC is attained for the clinical study prior to enrolling subjects. The PI will also ensure that documentation of approval is maintained for the duration of the study.

The PI will ensure that the Sponsor is notified of any withdrawal of EC approval within 5 working days of such occurrence. If approval is terminated or suspended, the PI will promptly notify the Sponsor and provide written explanation.

### 8.2 Regulatory Agencies and Competent Authority

The Sponsor will obtain approval from the local regulatory agency or competent authority (CA), Health Canada, before the start of the clinical trial, if necessary, per applicable local laws and regulations. Any additional requirements imposed by the EC or CA shall be followed, when applicable.



## 8.3 Management of Protocol Modifications and Amendments

Substantial amendments will only be implemented after EC approval.

A deviation is any instance(s) of failure to follow, intentionally or unintentionally, the requirements of the protocol. Under emergency circumstances, deviations from the protocol to protect the rights, safety, and wellbeing of human subjects may proceed without prior approval of the Sponsor and the EC/CA. Such deviations shall be documented and reported to the Sponsor and the EC as soon as possible. Deviations will be reported as:

- **Critical Deviations:** Deviations that significantly affect the safety, efficacy, integrity, or conduct of the study. These deviations must be reported to the Sponsor no later than 5 working days from awareness of occurrence and reported to the EC per the deviation reporting policy.
- **Non-Critical Deviations:** Protocol deviations that do not significantly affect the safety, efficacy, integrity, or conduct of the trial. These deviations must be documented on the CRF Protocol Deviation page and will be reviewed by the study monitor.

Non-substantial modifications may be made during the normal course of device optimization, maintenance, and feasibility testing. Non-substantial modifications will be communicated to the CA as soon as possible, if applicable, and to the EC per their policy.

## 8.4 Participant Information and Informed Consent

The investigator will explain to each participant the nature of the study, its purpose, the procedures involved, the expected duration of exposure to the investigational device, the potential risks and benefits, and any potential discomforts. Each participant will be informed that participation in the study is voluntary, that he/she may withdraw from the study at any time, and that withdrawal of consent will not affect his/her subsequent medical assistance and treatment. The participant must be informed that his/her medical records may be examined by authorized individuals other than their treating physician.

All participants for the study will be provided with an ICF, describing the study and providing sufficient information to allow the participant to make an informed decision about his/her participation in the study. Informed consent documents will be subject to approval by the EC prior to enrolling subjects in the study.

The participant should read and consider the statement before signing and dating the ICF, and shall be given a copy of the signed document. The ICF must also be signed and dated by the investigator (or his/her designee), and it shall be retained as part of the study records.

## 8.5 Early Termination of the Study

The Sponsor may terminate the study prematurely according to certain circumstances. Examples of such circumstances include ethical concerns, insufficient participant recruitment, participant safety concerns, alterations in accepted clinical practice that make the continuation of a clinical trial unwise, early evidence of benefit or harm of the research product, or for any other reason.





## **9. STATISTICAL METHODS**

### **9.1 Statistical Hypothesis**

No statistical hypothesis is being tested in this study.

### **9.2 Sample Size Determination**

The sample size is based on the Sponsor's previous clinical experience and the expectation that enough procedures using the OEC Elite will be performed to demonstrate clinical performance.

### **9.3 Statistical Analysis**

No statistical analysis is prospectively planned.

#### **9.3.1 Interim Analysis**

No interim analyses are intended to be conducted as part of this study.

### **9.4 Handling of Missing Data**

Analysis will be based on collected data, and no imputation will be done for missing data.

### **9.5 Deviation(s) from the Original Statistical Plan**

Any changes or deviations from the original statistical plan specified in this protocol will be described and justified in study final report, per ISO 14155:2011.

## **10. QUALITY ASSURANCE AND CONTROL**

### **10.1 Data Management**

Data management processes for handling study data will be maintained by the Sponsor.

#### **10.1.1 Completion of Case Report Forms (CRFs)**

The data reported on the CRFs shall be derived from source documents and be consistent with these source documents. Paper CRFs will be used to collect data. The Sponsor will provide CRFs and train study staff on completion of CRFs using Good Documentation Practices (GDP). CRF Completion Guidelines (CCG) may be provided by the Sponsor to help facilitate training.

CRFs are to be completed as information becomes available at the site. CRFs should be signed by indicated parties, in indicated area(s), to certify the contents of the form. The PI is ultimately responsible for ensuring completion of CRFs.

If discrepancies are discovered on paper CRFs during monitoring, the Sponsor's representative will ensure that the study staff makes necessary corrections directly to the CRF(s) prior to collection.

Following CRF collection, the Sponsor will review the data. A Data Clarification Form (DCF) may be provided to the site to correct or clarify discrepancies.

If a site discovers discrepancies after CRF collection, the site may notify the Sponsor and request data modification.



### 10.1.2 Data Handling and Record Keeping

All documents and data shall be produced and maintained in a manner that assures control and traceability.

### 10.1.3 Source Data and Documents

Source data includes information in original records, certified copies of original records of clinical findings, observations, or other activities for the study. Source documents for each subject must be retained throughout the investigation, including printed or electronic documents containing source data. Elements should include:

- **Source data and documentation** relevant to data recorded for subject screening and CRF corroboration.
- **Subject records** containing the completed ICFs and CRFs.
- **Regulatory binder** containing the protocol and any subsequent amendments, EC submissions and approvals, blank ICF(s), and site logs.
- **Reference manuals** containing investigator responsibilities, Sponsor, AE/SAE and informed consent guidelines, applicable study aids and training materials, and supplier instructions.

The PI or institution shall provide direct access to source data during and after the clinical investigation for monitoring, audits, EC review, and regulatory authority inspections.

### 10.1.4 Archiving

All study data must be archived for a minimum of three (3) years after study termination or premature termination of the clinical trial. No source documents or study records will be destroyed without Sponsor notification and approval.

## 11. MONITORING PLAN

In collaboration with the site, the Sponsor will ensure proper monitoring of the study to confirm that all the research requirements are met. Monitoring visits will oversee the progress of a clinical investigation and ensure that it is conducted, recorded, and reported in accordance with the protocol, written procedures, GCP ISO 14155:2011, and the applicable regulatory requirements.

### 11.1 Confidentiality and Data Protection

The investigator affirms and upholds the principle of the participant's right to privacy, and the investigator shall comply with applicable privacy laws. Especially, anonymity of the participants shall be guaranteed when presenting the data at scientific meetings or publishing data in scientific journals.

All individual subject medical information obtained as a result of this study will be considered confidential, and disclosure to third parties will be prohibited. Subject confidentiality will be further ensured by utilizing subject identification code numbers. For data verification purposes, authorized representatives of the Sponsor, CA, or EC may require direct access to parts of the medical records relevant to the study, including subject medical history.

#### 11.1.1 Storage of Images and Associated Health Data

Images will be collected or disclosed to the Sponsor as part of this study. No patient information beyond what is captured on the associated Case Report Forms will be collected. Fully de-identified data and images, which have had all personal identifying information removed, may be stored and used by the Sponsor indefinitely. The Sponsor and/or its authorized representatives may use any de-identified data collected in this study for future technology and engineering development, education, marketing, or other possible uses.





---

## 11.2 Publication Policy

The results of this study may not be used in future publications



---

## REFERENCES

1. ISO. *Clinical investigation of medical devices for human subjects - Good Clinical Practice*: International Organization for Standardization; 2011. ISO 14155:2011(E).
2. Miller DL. Overview of contemporary interventional fluoroscopy procedures. *Health Physics*. 2008;95(638):638-644.
3. Miller DL, Vano E, Bartal G, et al. Occupational Radiation Protection in Interventional Radiology: A Joint Guideline of the Cardiovascular and Interventional Radiology Society of Europe and the Society of Interventional Radiology. *J Vasc Interv Radiology*. May 2010;21(5):607-615.
4. Palacio E, Ribeiro A, Gavassi B, et al. Exposure of the surgical team to ionizing radiation during orthopedic surgical procedures. *Revista Brasileira De Ortopedia (RBO)*. 2014;49(3):227-232.
5. Ho P, Cheng SWK, Wu PM, et al. Ionizing radiation absorption of vascular surgeons during endovascular procedures. *Journal of Vascular Surgery*. September 2007;46(3):455-459.
6. Sullivan TM, Taylor SM, Blackhurst DW, et al. Has endovascular surgery reduced the number of open vascular operations performed by an established surgical practice. *Journal of Vascular Surgery*. September 2002;36(3):514-519.
7. Mayberg MR, Winn HR. Endarterectomy for Asymptomatic Carotid Artery Stenosis. *Journal of the American Medical Association*. May 1995;273(18):1459-1461.
8. Food and Drug Administration Center for Devices and Radiological Health. Guidance for Industry and Food and Drug Administration Staff: Guidance for the Submission of 510(k)s for Solid State X-ray Imaging Devices. 2016.



## APPENDIX A – STUDY SITE AND INVESTIGATOR LIST

The following investigators at each study site will be responsible for the conduct of this study:

<b>Investigator(s):</b> <sup>1</sup>	<b>Investigator Name, Dr. Theodore Rapanos</b> <i>Associate Professor</i> <i>Division of Vascular Surgery</i> <b>Tel:</b> 905-521-2100 x44652 <b>e-mail:</b> rapanost@mcmaster.ca	<b>Site Name</b> Hamilton General Hospital <b>Address:</b> 237 Barton St. East Hamilton, ON L8L 2X2
	<b>Investigator Name, Dr. Adnan Hadziomerovic</b> , <i>Clinical Associate Professor and head of the Angio Interventional Program / Department of Medical Imaging</i> <b>Tel:</b> 613-744-1241 <b>e-mail:</b> ahadziomerovic@toh.on.ca	<b>Site Name</b> The Ottawa Hospital <b>Address:</b> 501 Smyth Road Ottawa, Ontario K1H 8L6

<sup>1</sup> The role of the **Principal Investigator** is to implement and manage the conduct of the investigation as well as ensure data integrity and the rights, safety, and well-being of humans involved in the study [ISO 14155:2011 9.1]. **Co-Investigators** share all responsibilities of the **Principal Investigator**, and **Sub-investigators** share only those responsibilities designated by the **Principal Investigator**.